followup
chang
lung
function
lung
radiograph
pictur
sever
acut
respiratori
syndrom
sar
patient
discharg
xiaotangshan
hospit
beij
regularli
receiv
examin
analyz
retrospect
treatment
strategi
patient
method
surviv
sar
patient
seen
least
twice
within
month
discharg
underw
sarsassoci
coronaviru
sarscov
igg
antibodi
test
pulmonari
function
test
chest
radiographi
andor
highresolut
ct
hrct
examin
chines
pla
gener
hospit
treatment
receiv
xiaotangshan
hospit
analyz
retrospect
correl
later
statu
posit
sarsco
viru
igg
antibodi
result
seen
patient
patient
still
pulmonari
diffus
abnorm
dlco
predict
compar
survivor
posit
sarscov
igg
antibodi
result
dlco
predict
patient
neg
sarscov
igg
result
found
patient
posit
sarscov
igg
result
lung
diffus
abnorm
endur
much
longer
cours
fever
receiv
larger
dose
glucocorticoid
well
higher
ratio
oxygen
inhal
noninvas
ventil
treatment
patient
patient
posit
sarscov
igg
result
lung
diffus
abnorm
underw
pulmonari
function
test
approxim
month
dlco
improv
patient
patient
patient
lung
diffus
abnorm
patient
show
lung
fibrot
chang
lung
imag
examin
patient
show
improv
lung
fibrot
chang
month
later
conclus
find
suggest
lung
fibrot
chang
caus
sar
diseas
occur
mostli
sever
sick
patient
may
selfrehabilit
dlco
score
might
sensit
hrct
evalu
lung
fibrot
chang
chest
rehabilit
patient
sarscov
studi
observ
chang
lung
lesion
discharg
undergo
rehabilit
sar
patient
via
lung
function
test
lung
imag
examin
retrospect
analysi
diseas
cours
therapi
record
board
beij
xiaotangshan
hospit
approv
studi
use
case
file
patient
gave
inform
consent
studi
extend
juli
septemb
includ
sar
patient
discharg
beij
xiaotangshan
hospit
individu
clinic
diagnosi
base
clinic
diagnosi
standard
sar
patient
issu
ministri
chines
public
health
patient
studi
met
specifi
criteria
discharg
first
followup
visit
patient
juli
august
although
rehabilit
sar
patient
well
enough
perform
daili
activ
followup
studi
complain
limit
physic
abil
gener
weak
andor
short
breath
clinic
followup
entir
new
entiti
literatur
refer
guidanc
cours
sar
therefor
reli
perform
followup
pulmonari
function
test
frontal
chest
radiographi
cxr
andor
highresolut
ct
serum
sarscov
igg
antibodi
examin
chines
pla
gener
hospit
beij
approxim
month
first
followup
patient
underw
pulmonari
function
test
lung
imag
serum
sarscov
igg
antibodi
examin
observ
rehabilit
chang
lung
injuri
examin
perform
first
followup
visit
repeat
second
visit
second
followup
obtain
averag
sd
day
rang
day
first
visit
rehabilit
sar
patient
underw
standard
pulmonari
function
test
model
sensormed
yorba
linda
ca
fev
vital
capac
vc
fvc
total
lung
capac
diffus
capac
lung
carbon
monoxid
dlco
dlco
constant
dlcova
measur
mean
singlebreath
test
hemoglobin
valu
also
taken
correct
dlco
result
compar
ageand
sexmatch
control
subject
express
percentag
predict
valu
pulmonari
function
regard
abnorm
dlco
predict
valu
cxr
perform
first
followup
visit
everi
rehabilit
sar
patient
cxr
abnorm
found
dlco
predict
valu
despit
normal
cxr
patient
sent
hrct
scan
ge
lightspe
ge
medic
system
milwauke
wi
section
thick
gap
supin
posit
scan
inspir
second
per
scan
kilovolt
three
nonblind
radiologist
view
consol
assess
cxr
ct
imag
final
conclus
establish
consensu
segment
lung
review
groundglass
opacif
interstiti
thicken
bronchiectasi
architectur
distort
abnorm
magnifi
use
zoom
function
examin
intralobular
interstiti
interlobular
septal
peribronchovascular
interstiti
thicken
presenc
absenc
nodul
mass
cavit
calcif
emphysema
also
note
presenc
parenchym
band
irregular
interfac
bronchovascular
pleural
mediastin
thicken
interstitium
traction
bronchiectasi
evid
fibrot
chang
sarscov
igg
antibodi
present
serum
specimen
rehabilit
sar
patient
test
enzymelink
immunosorb
assay
bgigbi
biotech
compani
beij
roc
specimen
test
bgigbi
biotech
compani
well
polystyren
micropl
strip
coat
two
recombin
sarscov
antigen
well
character
serum
dilut
diluent
buffer
incub
coat
well
min
well
wash
five
time
wash
buffer
enzymelabel
antihuman
igg
work
dilut
l
ad
incub
min
wash
five
time
wash
buffer
tetramethylbenzidin
substrat
ad
well
presenc
specif
antibodi
indic
presenc
yellow
color
substrat
addit
reaction
termin
addit
hydrochlor
acid
intens
color
measur
spectrophotometr
nm
proport
amount
antibodi
specimen
optic
densiti
od
obtain
yaxi
plot
lotspecif
standard
concentr
xaxi
result
linear
calibr
curv
od
valu
posit
control
neg
control
calcul
cutoff
valu
igg
calcul
mean
sd
read
given
blood
donor
control
sera
od
valu
cutoff
valu
indic
posit
result
sarscov
igg
total
rna
examin
sputum
urin
fece
whole
blood
extract
qiaamp
rna
blood
mini
kit
qiagen
valencia
ca
accord
instruct
manufactur
rna
dissolv
l
diethyl
pirocarbonatetr
water
contain
u
deoxyribonucleas
promega
madison
wi
nest
revers
transcriptasepolymeras
chain
reaction
pcr
method
primarili
use
ensur
specif
size
pcr
product
basepair
retrospect
review
analyz
data
record
sar
patient
onset
throughout
hospit
stay
includ
durat
persist
fever
total
dosag
glucocorticoid
patient
requir
supplement
oxygen
number
noninvas
ventil
treatment
data
express
mean
sd
unless
otherwis
indic
statist
analys
done
oneway
analysi
varianc
anova
studentnewmankeul
test
multipl
comparison
use
statist
analysi
softwar
stata
window
statacorp
colleg
station
tx
evalu
result
studi
statist
test
level
use
determin
signific
consid
p
valu
juli
septemb
total
sar
patient
follow
least
twice
discharg
men
women
mean
age
year
age
rang
year
mean
time
discharg
first
followup
day
rang
day
rehabilit
sar
patient
expect
sampl
test
neg
viral
rna
serum
sarscov
igg
antibodi
examin
followup
requir
serum
sarscov
igg
antibodi
test
serum
sampl
test
least
two
time
posit
result
seen
patient
neg
result
seen
patient
patient
posit
result
patient
pulmonari
diffus
abnorm
dlco
predict
patient
neg
result
pulmonari
diffus
abnorm
dlco
predict
one
histori
copd
pulmonari
fibrosi
chang
histori
organ
pneumonia
diseas
p
tabl
patient
posit
sarscov
igg
result
dlco
predict
older
patient
posit
sarscov
igg
result
dlco
predict
patient
neg
sarscov
igg
result
p
tabl
patient
posit
sarscov
igg
antibodi
result
dlco
predict
patient
underw
pulmonari
function
test
least
twice
second
followup
appoint
averag
day
rang
day
first
visit
tabl
show
result
pulmonari
function
test
vc
fev
dlco
dlcova
second
examin
reveal
improv
score
compar
first
examin
tabl
residu
abnorm
cxr
hrct
imag
sar
patient
mainli
display
interstiti
thicken
tabl
fig
cours
sar
diseas
durat
fever
patient
posit
sarscov
igg
antibodi
result
dlco
predict
longer
compar
patient
posit
sarscov
igg
result
dlco
predict
patient
neg
sarscov
igg
result
dose
glucocorticoid
use
fraction
inspir
oxygen
concentr
number
noninvas
posit
pressur
ventil
nippv
treatment
patient
posit
sarscov
igg
result
dlco
predict
also
higher
patient
tabl
patient
none
intub
receiv
invas
mechan
ventil
patient
receiv
nippv
tabl
sarscov
infect
human
bodi
respiratori
tract
replic
epitheli
cell
respiratori
tract
pneumocyt
host
immun
respons
sarscov
infect
lead
lymphocyt
product
macrophag
infiltra
tion
alveolar
septa
interstiti
compart
patient
sever
sar
pulmonari
lesion
may
progress
prolifer
fibrosi
phase
prolifer
phase
cellular
compon
myofibroblast
fibroblast
produc
collagen
type
iii
collagen
type
rehabilit
phase
patient
still
lung
fibrot
chang
complain
limit
physic
function
gener
weak
andor
short
breath
affect
pulmonari
function
life
qualiti
followup
visit
found
rehabilit
sar
patient
express
persist
sar
viru
infect
detect
sarscov
rna
examin
result
show
rehabilit
patient
infect
studi
patient
show
neg
sarscov
igg
antibodi
result
least
two
examin
hint
might
misdiagnos
chines
clinic
diagnosi
standard
center
diseas
control
prevent
sar
case
definit
emphas
import
epidemiolog
histori
clinic
manifest
cxr
chang
clinic
diagnos
sar
diseas
laboratori
test
center
diseas
control
prevent
sar
case
definit
especi
emphas
import
confirm
sar
detect
dynam
chang
titrat
specif
antibodi
sarscov
posit
detect
sarscov
rna
pcr
chines
clinic
diagnosi
standard
mention
import
laboratori
sarscov
test
sar
case
confirm
might
caus
exist
misdiagnos
sar
case
therefor
retrospect
followup
studi
exclud
case
ensur
data
accuraci
studi
found
patient
whose
sarscov
igg
antibodi
result
posit
also
pulmonari
diffus
abnorm
dlco
predict
analyz
result
second
pulmonari
function
examin
compar
result
first
show
patient
patient
improv
pulmonari
diffus
function
p
rehabilit
patient
pulmonari
radiolog
residu
caus
sar
diseas
present
pulmonari
fibrot
chang
patient
show
improv
hrct
scan
month
suggest
mechan
lung
injuri
lung
fibrot
chang
caus
sarscov
might
differ
pathophysiolog
process
compar
diseas
lung
sar
patient
lung
fibrot
chang
seem
abil
selfrehabilit
pulmonari
diffus
test
might
sensit
hrct
evalu
lung
fibrot
chang
vs
think
radiolog
resolut
pneumon
process
may
lag
behind
clinic
pictur
although
studi
limit
approxim
followup
lung
function
test
reflect
earlier
resolut
diffus
impair
compar
hrct
retrospect
analyz
data
sar
patient
includ
durat
persist
fever
treatment
inform
found
patient
posit
sarscov
igg
result
dlco
predict
older
compar
patient
posit
sarscov
igg
result
dlco
predict
neg
sarscov
igg
result
durat
fever
dosag
glucocorticoid
usag
fraction
inspir
oxygen
number
nippv
treatment
patient
posit
sarscov
igg
result
dlco
predict
also
longer
may
explain
older
sar
patient
sever
symptom
younger
patient
spite
aggress
therapi
method
sequela
rate
older
rehabilit
sar
patient
present
higher
rate
lung
fibrot
chang
conclus
sar
associ
consider
rate
morbid
mortal
acut
phase
signific
proport
patient
surviv
acut
ill
impair
overal
function
capac
health
statu
first
month
discharg
hospit
howev
longterm
effect
still
larg
unknown
necessari
followup
patient
time
comprehens
assess
detect
appropri
manag
case
persist
emerg
sequela
exist
